Abstract 4360
Background
GBM is the most common primary brain tumor. Survival is poor with standard surgery followed by radiotherapy (RT) and temozolomide (TMZ). Pseudo-progression on MRI is well described post-RT, particularly within the first 3 months, and confounds response assessment. Whilst not previously described for drug treatment alone, anecdotal cases were described in a Phase 1 study of depatuxizumab mafodotin (depatux-m). Depatux-m is an antibody-drug conjugate, comprised of a tumor-specific anti-EGFR antibody linked to a microtubule cytotoxin, monomethyl auristatin F, that demonstrated promising antitumor activity in adult GBM pts with EGFR-amplified tumors. This exploratory study will determine if depatux-m exhibits radiologically evident treatment effects in pts with GBM, i.e. drug induced pseudo-progression.
Methods
This non-interventional study enrolls pts with GBM who underwent tumor debulking surgery after MRI evidence suggested treatment failure in Phase 1-3 depatux-m trials. Pts had received depatux-m alone or in combination with TMZ. Resected tumor tissue is formalin-fixed, paraffin-embedded and centrally reviewed. Radiographic assessments were collected per original study protocol (typically q8 wks), or as clinically indicated, and centrally reviewed. Clinical response is evaluated by RANO criteria. This study will assess correlation between radiographic and histologic evidence of disease progression after depatux-m treatment. Exploratory endpoints are progression-free survival and overall survival.
Results
As of April 2018, 7 pts with recurrent GBM were enrolled at 2 sites in Australia. All pts completed RT at a minimum of 11 months (range 11-26) prior to re-resection. 4 pts had histological confirmation of recurrence prior to treatment.
Conclusions
Histology showed that 57% (4/7) of pts with disease progression by RANO criteria after depatux-m, with or without TMZ, had predominantly treatment effect per local pathologist assessment. Central review indicated that of these 4 pts, 2 pts were ≥75% necrotic and 2 showed complete absence of tumour. 2 pts had histological confirmation of recurrence prior to treatment. Cases and associated clinical impact are presented.
Clinical trial identification
Legal entity responsible for the study
AbbVie Inc.
Funding
AbbVie Inc.
Editorial Acknowledgement
Medical writing support was provided by Ana Mrejeru, Ph.D., of AbbVie.
Disclosure
H.K. Gan: Consulting/advisory role: AbbVie; Speakers’ bureau: Ignyta, Bristol-Myers Squibb; Research funding: AbbVie; Travel, accommodations, expenses: Ignyta. E. Kennedy, D. Maag: Employee and stock: AbbVie. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract